Patents by Inventor Harry Ralph Howard

Harry Ralph Howard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES
    Publication number: 20020091118
    Abstract: The present invention relates to compounds of the formula 1
    Type: Application
    Filed: November 6, 2001
    Publication date: July 11, 2002
    Applicant: Pfizer Inc.
    Inventor: Harry Ralph Howard
  • Aralkyl and aralkylidene heterocyclic lactams and imides
    Publication number: 20020091119
    Abstract: The present invention relates to compounds of the formula 1
    Type: Application
    Filed: November 6, 2001
    Publication date: July 11, 2002
    Applicant: Pfizer Inc.
    Inventor: Harry Ralph Howard
  • Aralkyl and aralkylidene heterocyclic lactams and imides
    Publication number: 20020072519
    Abstract: The present invention relates to compounds of the formula 1
    Type: Application
    Filed: November 6, 2001
    Publication date: June 13, 2002
    Applicant: Pfizer Inc.
    Inventor: Harry Ralph Howard
  • Aralkyl and aralkylidene heterocyclic lactams and imides
    Patent number: 6403592
    Abstract: The present invention relates to compounds of the formula wherein R1, R2, R3, X, Y and the dashed line are defined as in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. These compounds are useful as psychotherapeutic agents.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: June 11, 2002
    Assignee: Pfizer INC
    Inventor: Harry Ralph Howard
  • Aralkyl and aralkylidene heterocyclic lactams and imides
    Patent number: 6380186
    Abstract: The present invention relates to compounds of the formula wherein R1, R2, R3, X, Y and the dashed line are defined as in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. These compounds are useful as psychotherapeutic agents.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: April 30, 2002
    Assignee: Pfizer INC
    Inventor: Harry Ralph Howard
  • Aralkyl and aralkylidene heterocyclic lactams and imides
    Publication number: 20020049214
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: December 8, 2000
    Publication date: April 25, 2002
    Inventors: Megan Ann Gibbs, Harry Ralph Howard, Jeffrey Scott Sprouse, Joel Barry Schachter, Phillip Branch Chappell
  • Optically active 3-[(2-Piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT 1D receptor selective antagonists
    Publication number: 20010039280
    Abstract: The present invention relates to optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinones and pharmaceutically acceptable salts thereof, to processes for their preparation, to isotopically-labeled analogs thereof, to pharmaceutical compositions comprising them and to their medicinal use as selective antagonists of the 5-HT1D receptor. The compounds of the invention are useful in treating depression, obsessive-compulsive disorder (OCD) and diseases, disorders or conditions for which a 5-HT1D receptor selective antagonist is therapeutically indicated.
    Type: Application
    Filed: December 19, 2000
    Publication date: November 8, 2001
    Inventors: Harry Ralph Howard, Stephane Caron, Mavis Diane Adam
  • Arylacrylamide derivatives
    Patent number: 6258953
    Abstract: Compounds of the formula wherein R1, R2, R3, R4, R5 and X are defined as in the specification. These compounds are useful psychotherapeutics and are potent serotonin (5-HT1) agonists and antagonists.
    Type: Grant
    Filed: May 28, 1997
    Date of Patent: July 10, 2001
    Assignee: Pfizer Inc.
    Inventors: Harry Ralph Howard, Barbara Eileen Segelstein
  • NK-1 receptor antagonists for the treatment of cancer
    Patent number: 6194436
    Abstract: The present invention relates to the use of certain NK-1 receptor antagonists, as, for example, substance P receptor antagonists, to treat cancer patients, particularly cancer patients afflicted with a small cell lung carcinoma, neuroendocrine tumor or extrapulmonary small cell carcinoma.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: February 27, 2001
    Assignee: Pfizer Inc.
    Inventor: Harry Ralph Howard
  • NK-1 receptor antagonists for the treatment of cancer
    Patent number: 5990125
    Abstract: The present invention relates to the use of certain NK-1 receptor antagonists (e.g., substance P receptor antagonists) to treat cancer patients, particularly cancer patients afflicted with a small cell lung carcinoma, APUDoma, astrocytoma, neuroendocrine tumor or extrapulmonary small cell carcinoma.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: November 23, 1999
    Assignee: Pfizer Inc.
    Inventor: Harry Ralph Howard